Table 3.
Lifestyle factor | 10‐year TC risk <3.0% | 10‐year TC risk 3.0–4.9% | 10‐year TC risk >5.0% | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast cancer | Breast cancer | Breast cancer | |||||||||||||
Alcohol (g/day) | n total | % | n all cases | Adj.1 OR | [95% CI] | n total | % | n all cases | Adj.1 OR | [95% CI] | n total | % | n all cases | Adj.1 OR | [95% CI] |
0 | 5,809 | 20.8 | 64 | Reference | 3,130 | 17.3 | 45 | Reference | 1,249 | 17.3 | 39 | Reference | |||
0.1–9.9 | 17,287 | 62.0 | 218 | 1.09 | [0.82, 1.46] | 11,144 | 61.7 | 199 | 1.34 | [0.95, 1.90] | 4,404 | 60.9 | 135 | 1.02 | [0.70, 1.48] |
10.0–40.0 | 4,806 | 17.2 | 70 | 1.13 | [0.79, 1.62] | 3,781 | 20.9 | 77 | 1.51 | [1.02, 2.24] | 1,580 | 21.8 | 52 | 1.16 | [0.75, 1.81] |
10 g/day | 27,901 | 100 | 352 | 1.11 | [0.97 1.27] | 18,054 | 100 | 321 | 1.06 | [0.93, 1.22] | 7,233 | 100 | 226 | 1.07 | [0.91 1.26] |
Alcohol (g/day) | n total | % | ER+ cases2 (n) | Adj.1 OR | [95% CI] | n total | % | ER+ cases2 (n) | Adj.1 OR | [95% CI] | n total | % | ER+ cases2 (n) | Adj.1 OR | [95% CI] |
0 | 5,801 | 20.8 | 45 | Reference | 3,126 | 17.3 | 34 | Reference | 1,244 | 17.3 | 29 | Reference | |||
0.1–9.9 | 17,266 | 62.0 | 165 | 1.21 | [0.86, 1.71] | 11,128 | 61.7 | 154 | 1.41 | [0.95, 2.11] | 4,385 | 60.9 | 102 | 1.05 | [0.68, 1.61] |
10.0–40.0 | 4,794 | 17.2 | 51 | 1.25 | [0.82, 1.92] | 3,777 | 21.0 | 61 | 1.63 | [1.03, 2.56] | 1,577 | 21.8 | 37 | 1.12 | [0.67, 1.87] |
10 g/day | 27,860 | 100 | 261 | 1.16 | [0.99, 1.35] | 18,030 | 100 | 249 | 1.12 | [0.97 1.30] | 7,206 | 100 | 168 | 1.08 | [0.90 1.30] |
Physical activity | n total | % | n all cases | Adj.1 OR | [95% CI] | n total | % | n all cases | Adj.1 OR | [95% CI] | n total | % | n all cases | Adj.1 OR | [95% CI] |
Total activity (MET‐hr/day) | |||||||||||||||
<40.0 | 9,647 | 34.6 | 106 | Reference | 6,816 | 37.8 | 121 | Reference | 2,778 | 38.4 | 82 | Reference | |||
40.0–44.9 | 9,594 | 34.4 | 143 | 1.40 | [1.07, 1.82] | 6,644 | 36.8 | 116 | 0.98 | [0.75, 1.28] | 2,653 | 36.7 | 86 | 1.09 | [0.79, 1.51] |
≥45.0 | 8,660 | 31.0 | 104 | 1.27 | [0.95, 1.70] | 4,594 | 25.4 | 83 | 1.18 | [0.88, 1.58] | 1,802 | 24.9 | 59 | 1.20 | [0.84, 1.72] |
5 MET‐hr/day increase | 27,901 | 100 | 352 | 1.00 | [0.92, 1.09] | 18,054 | 100 | 321 | 1.04 | [0.95 1.14] | 7,233 | 100 | 226 | 1.05 | [0.94, 1.18] |
Moderate activity (hr/day) | |||||||||||||||
<2.0 | 10,200 | 36.6 | 124 | Reference | 7,359 | 40.8 | 124 | Reference | 3,015 | 41.7 | 91 | Reference | |||
2.0–4.9 | 8,630 | 30.9 | 120 | 1.05 | [0.81, 1.37] | 5,865 | 32.5 | 116 | 1.12 | [0.86, 1.46] | 2,346 | 32.4 | 75 | 1.10 | [0.79, 1.52] |
≥5.0 | 9,071 | 32.5 | 108 | 1.11 | [0.84, 1.46] | 4,829 | 26.7 | 81 | 1.09 | [0.81, 1.46] | 1,872 | 25.9 | 60 | 1.17 | [0.82, 1.66] |
1 hr/day increase | 27,901 | 100 | 352 | 1.00 | [0.96, 1.04] | 18,054 | 100 | 321 | 1.02 | [0.98, 1.07] | 7,233 | 100 | 226 | 1.03 | [0.98, 1.08] |
Vigorous activity (hr/day) | |||||||||||||||
<0.2 | 18,437 | 66.1 | 225 | Reference | 12,217 | 67.7 | 216 | Reference | 4,981 | 68.9 | 156 | Reference | |||
≥0.2 | 9,465 | 33.9 | 127 | 1.14 | [0.91 1.44] | 5,837 | 32.3 | 105 | 1.08 | [0.85 1.38] | 2,252 | 31.1 | 70 | 0.99 | [0.73, 1.34] |
1 hr/day increase | 27,901 | 100 | 352 | 1.08 | [0.81, 1.45] | 18,054 | 100 | 321 | 1.26 | [0.93, 1.69] | 7,233 | 100 | 226 | 0.84 | [0.52, 1.37] |
Recreational activity (hr/day) | |||||||||||||||
<1.5 | 9,939 | 35.6 | 117 | Reference | 7,009 | 38.8 | 110 | Reference | 2,824 | 39.0 | 88 | Reference | |||
1.5–2.5 | 7,947 | 28.5 | 94 | 0.96 | [0.72, 1.28] | 5,224 | 28.9 | 96 | 1.16 | [0.87 1.55] | 2,149 | 29.7 | 72 | 1.13 | [0.81, 1.56] |
≥2.5 | 10,016 | 35.9 | 141 | 1.11 | [0.85, 1.44] | 5,821 | 32.3 | 115 | 1.26 | [0.95, 1.66] | 2,260 | 31.3 | 66 | 0.94 | [0.67, 1.33] |
1 hr/day increase | 27,901 | 100 | 352 | 1.02 | [0.97, 1.08] | 18,054 | 100 | 321 | 1.03 | [0.97, 1.10] | 7,233 | 100 | 226 | 0.95 | [0.87, 1.04] |
Adjusted for age, BMI (<25.0, 25.0–29.9, ≥30.0 kg/m2), ethnicity (European ancestry yes/no), oral contraceptive use (ever, never), use of menopausal hormone therapy (never, ever), family history of breast cancer in mother or sister(s) (yes, no), age at menarche (<13, 13, 14, ≥15 years), parity and age at first birth (nulliparous; one or two births, age at first birth <26 years; one or two births, age at first birth ≥26 years; ≥3 births, age at first birth <26 years; ≥3 births, age at first birth ≥26 years), education level (secondary school, high school, university or higher, other) and menopausal status (post or premenopausal).
Breast cancer patients with ER− status were excluded from the analysis (n = 101).